Liquidia breaks ground for manufacturing facility at Pathway Triangle

Liquidia officials were joined by Pathway Triangle leaders for a groundbreaking ceremony for the company’s new manufacturing facility at 1000 Science Drive in Morrisville. 

The company has leased approximately 70,000 square feet of commercial space to build a state-of-the-art facility, targeted for occupancy in 2026. The new space will include production cleanroom space to house manufacturing lines and analytical labs to support commercial supply of Yutrepia, the company’s inhalation powder form of treprostinil, for the treatment of two types of cardiopulmonary disease: pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). 

In May, the U.S. Food and Drug Administration approved Yutrepia. 

Liquidia is a publicly held company. In the company’s early start-up years, the North Carolina Biotechnology Center helped Liquidia’s product-commercialization activities by funding postdoctoral industrial fellowships totaling more than $83,000.